Clinical trials
Recurrent clinical trials
Below are recruiting recurrent clinical trials, each written for real people, not researchers. We’re tracking 1,384 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05724719Recruiting
Study brain signals after a first unprovoked seizure
This study looks at people ages 18 to 65 after they have a first seizure that is not clearly triggered. It also compares them with healthy volunteers to better understand what might predict whether seizures come back.
Halifax, Nova ScotiaAges 18–65 - NCT07703735Enrolling by invitation
Survival after ABO-mismatch living donor liver transplant for liver cancer
This trial looks at how well patients with liver cancer do after receiving a living donor liver transplant that is not the same blood type. It compares survival and cancer return for these patients.
Ages 18 years+ - NCT07698886RecruitingPhase 2
Laser plus Geniwa gel for recurring genital warts
This trial tests whether adding a special gel (Geniwa gel) to standard laser treatment helps prevent genital warts from coming back. It may be an option for people who have already tried laser treatment but their warts returned.
Hanoi, None (International)Ages 18 years+ - NCT07705243RecruitingPhase 3
Maintenance therapy for advanced nasopharyngeal cancer
This trial tests a combination of two drugs (becotatug vedotin and an anti-PD1 immunotherapy) as maintenance treatment after initial chemotherapy for advanced nasopharyngeal cancer that has spread or returned. It's for people whose disease has not progressed after standard first-line treatment.
Guangzhou, GuangdongAges 18–75 - NCT07698899RecruitingPhase 1
Study of a new treatment for childhood brain and CNS cancers
This trial tests a radioactive drug (177Lu-DTPA-Omburtamab) given directly into the fluid around the brain for children and teens with certain brain cancers or cancers that have spread to the central nervous system. It aims to see if this treatment is safe and effective for tumors that have come back or not responded to other therapies.
Basking Ridge, New JerseyAges 3–22 - NCT01993498Recruiting
Study side effects of cancer treatment in localized breast or lung cancer
This study looks at long-term side effects from standard cancer treatments and how they affect daily life and resources. It may help improve care for people with breast or lung cancer that has not spread.
VillejuifAges 18 years+ - NCT04921527RecruitingPhase 3
Chiauranib with weekly paclitaxel for tough ovarian cancer
This Phase 3 trial tests whether chiauranib combined with weekly paclitaxel can shrink recurrent ovarian, fallopian tube, or primary peritoneal cancer that did not respond to platinum chemotherapy. It is designed for people who have limited treatment options after platinum-resistant or platinum-refractory disease.
Shanghai, ChinaAges 18–70 - NCT06650826Recruiting
Antibodies and blood clots in young adults
This study looks for certain antibodies in the blood of people aged 18 to 60 who have had a blood clot without a clear cause, or soon after an infection or vaccine, or who have had clots return despite treatment. It aims to understand why these clots happen.
BerlinAges 18–60 - NCT06390774RecruitingPhase 1
Study of SSGJ-705 for advanced cancers
This phase 1 trial tests a new targeted drug (SSGJ-705) for people with advanced solid tumors or lymphomas. Doctors will check safety and find the best dose, and there may be a chance the drug helps shrink or control the cancer.
Jinan, ShandongAges 18–75 - NCT07694674Recruiting
Comparing Biologic Drugs to Prevent Crohn's Return After Surgery
This trial compares different biologic medications to see which best prevents Crohn's disease from coming back after intestinal surgery. It may help you if you have had surgery for Crohn's and are starting a biologic drug soon after.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT07690579Recruiting
Prostate cancer disparities study
This study looks at how social, lifestyle, and other factors affect prostate cancer outcomes. It enrolls men who have chosen to have their prostate removed (radical prostatectomy) and agreed to join a biobank.
San Francisco, CaliforniaAges 18 years+ - NCT07690787RecruitingPhase 2
Study of JS207 for nasopharyngeal cancer
This trial tests a new drug, JS207, which targets two proteins (PD-1 and VEGF) that help cancer grow. It's for people with nasopharyngeal cancer that has not spread too much, and who have not had certain prior treatments.
Hong KongAges 18 years+ - NCT06617481RecruitingPhase 2
PET scan study for early prostate cancer recurrence
This trial uses a special PET scan to detect prostate cancer when your PSA level is slightly rising after prostate removal surgery. It aims to find cancer early so treatment decisions can be better informed.
Orlando, FloridaAges 18 years+ - NCT07683195Enrolling by invitation
Using CT scans to predict early stomach cancer return
This study uses information from CT scans done before stomach cancer surgery to see if it can predict whether the cancer may come back early. Researchers want to find patterns in the scans that might help doctors plan better follow-up care.
Jinan, ShandongAges 18–85 - NCT06251700Recruiting
AI-assisted colonoscopy and long-term polyp prevention
This study checks if using AI during colonoscopy helps prevent growths from coming back. You'd need to have been in an earlier AI-colonoscopy study and be willing to come back for a follow-up colonoscopy 3 years later.
Hong KongAges 18 years+ - NCT07678684RecruitingPhase 2
Study of HF1K16 plus bevacizumab for recurrent glioma
This trial tests a new combination of two drugs, HF1K16 and bevacizumab, for people whose glioma has come back or grown after prior treatment. It aims to see if this combination can help when standard options are no longer working or tolerable.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07673367RecruitingPhase 2
Nemtabrutinib with CAR T for relapsed mantle cell lymphoma
This trial tests adding a targeted pill (nemtabrutinib) to standard CAR T-cell therapy for people with mantle cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination works better than CAR T alone.
Nashville, TennesseeAges 18 years+ - NCT07668154RecruitingPhase 2
Testing SKB571 for advanced head and neck cancer
This study tests a new drug called SKB571 for people whose head and neck cancer (a type called squamous cell carcinoma) has come back or spread and cannot be surgically removed. The goal is to see if the drug is safe and effective.
ChengduAges 18–75 - NCT07668869Recruiting
Electric fields with targeted radiation vs. alone for recurrent brain cancer
This trial tests whether adding a precise, MRI-guided radiation treatment to tumor-treating electric fields (TTFields) can help people with recurrent glioblastoma. You may qualify if your tumor has come back 1 to 3 times after standard therapy and you haven't had certain prior treatments.
BydgoszczAges 18 years+ - NCT07671677Recruiting
BodyGuardian monitoring after AF ablation
This study tests using a portable heart monitor called BodyGuardian to check for atrial fibrillation returning after a procedure called ablation. It may help your doctor find irregular heartbeats early.
Delray Beach, FloridaAges 18 years+ - NCT06395870RecruitingPhase 1
Dual-target cell therapy for returning B-cell lymphoma
This trial tests a new cell therapy that targets two proteins (CD19 and CD20) found on certain lymphoma cells. It is for patients whose B-cell non-Hodgkin lymphoma has come back or not responded to at least two prior treatments. The goal is to see if this therapy can help control the cancer.
Hefei, AnhuiAges 18–75 - NCT06480604Recruiting
Probiotic for yeast infection prevention
This trial tests if taking a multi-strain probiotic daily can prevent repeat yeast infections in women who have had at least three infections in the past year.
Vadodara, GujaratAges 18–50 - NCT07657312RecruitingPhase 2
Infliximab to prevent side effects during myeloma treatment
This trial tests if infliximab, a drug that calms the immune system, can prevent cytokine release syndrome (a serious side effect) when patients receive teclistamab or talquetamab for multiple myeloma that has returned or not responded to treatment.
Columbus, OhioAges 18 years+ - NCT07657325Recruiting
Toripalimab for high-risk kidney cancer that has been removed
This trial tests whether the drug toripalimab can prevent kidney cancer from coming back in people who have had their kidney and any visible metastases surgically removed. It focuses on patients with high-risk features or who had some metastatic spots taken out completely.
Tianjin, Tianjin MunicipalityAges 18 years+
Hear when a new Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent?
- Yes. Clin2 currently lists 1,384 recruiting recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.